0
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

JAMA Dermatology a Century Ago |  April 01, 2013
PROPRIETARY REMEDIES AND THE DERMATOLOGIST.
JAMA Dermatol. 2013;149(4):398. doi:10.1001/jamadermatol.2013.2919.
Correspondence |  April 01, 2013
Using Hawthorne Effects to Improve Adherence in Clinical Practice: Lessons From Clinical Trials
Scott A. Davis, MA; Steven R. Feldman, MD, PhD
JAMA Dermatol. 2013;149(4):490-491. doi:10.1001/jamadermatol.2013.2843.
Correspondence |  April 01, 2013
Using Hawthorne Effects to Improve Adherence in Clinical Practice: Lessons From Clinical Trials—Reply
Joel M. Gelfand, MD, MSCE; Shuwei Wang, BS; Junko Takeshita, MD, PhD; et al.
JAMA Dermatol. 2013;149(4):490-491. doi:10.1001/jamadermatol.2013.2846.
Correction |  February 01, 2013
Error in “Methods” in: “Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis”
JAMA Dermatol. 2013;149(2):158. doi:10.1001/jamadermatol.2013.3334.
Study |  February 01, 2013
Association of Pediatric Psoriasis Severity With Excess and Central Adiposity:  An International Cross-Sectional Study
Amy S. Paller, MD; Katherine Mercy, MD; Mary J. Kwasny, ScD; et al.
JAMA Dermatol. 2013;149(2):166-176. doi:10.1001/jamadermatol.2013.1078.
Review |  January 01, 2013
Psoriasis and the Risk of Diabetes Mellitus:  A Systematic Review and Meta-analysis
April W. Armstrong, MD, MPH; Caitlin T. Harskamp, BA; Ehrin J. Armstrong, MD, MSc
JAMA Dermatol. 2013;149(1):84-91. doi:10.1001/2013.jamadermatol.406.
Evidence-Based Dermatology: Review |  December 01, 2012
Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis:  A Bayesian Network Meta-analysis
Vincent W. Lin, PharmD, MS; Sarah Ringold, MD, MS; Emily Beth Devine, PharmD, MBA, PhD
Arch Dermatol. 2012;148(12):1403-1410. doi:10.1001/2013.jamadermatol.238.
Research Letters |  December 01, 2012
Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular Psoriasis
Manuelle Viguier, MD, PhD; François Aubin, MD, PhD; Emmanuel Delaporte, MD; et al.
Arch Dermatol. 2012;148(12):1423-1425. doi:10.1001/2013.jamadermatol.80.
Correspondence |  November 01, 2012
Interleukin 12/23 Agents and Major Adverse Cardiovascular Events
Mark Lebwohl, MD
Arch Dermatol. 2012;148(11):1329. doi:10.1001/2013.jamadermatol.88.
Correspondence |  November 01, 2012
Peripheral Lymph Node Recurrence of Tuberculosis After Ustekinumab Treatment
Ana I. Sánchez-Moya, MD; Esteban Daudén, PhD
Arch Dermatol. 2012;148(11):1332-1333. doi:10.1001/archdermatol.2012.2958.

Sign In

Register for a FREE personal account

and access these and other features:

Register Now

Want to Subscribe?

Learn More about subscription options.

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

From The JAMA Network
JAMA
From the JAMA Network  |  May 15, 2013
Do TNF Inhibitors Reduce the Risk of Myocardial Infarction in Psoriasis Patients?
April W. Armstrong, MD, MPH
JAMA Pediatrics
Special Feature  |  Apr 2012
Picture of the Month—Diagnosis
JAMA
Review  |  August 24/31, 2011
Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events:  A Meta-analysis of Randomized Controlled Trials
Caitriona Ryan, MB, BAO, BCh; Craig L. Leonardi, MD; James G. Krueger, MD, PhD; et al.
JAMA
JAMA Patient Page  |  August 24/31, 2011
Psoriasis
Janet M. Torpy, MD; Alison E. Burke, MA; Robert M. Golub, MD
© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems